NCT02722408 - Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

July 31, 2017

Conditions

Hypercholesteremia

Interventions

DRUG

Gemcabene

300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.

Trial Locations (7)

Unknown

Westside Medical Associates of Los Angeles, Beverly Hills

Robarts Research Institute, London

Ecogene-21, Chicoutimi

Montreal Heart Institute, Montreal

Wolfson Medical Center Internal Medicine Dept., Holon

Center for Research, Prevention and Treatment of Atherosclerosis - Cardiology Department of Medicine Kiryat Hadassah, Jerusalem

Ziv Medical Center Internal Medicine Department, Safed